Phathom Financial Statements From 2010 to 2024

Stocks . USA . 
Stock . Phathom Pharmaceuticals
PHAT Stock  USD 9.09  0.25  2.68%   
Phathom Pharmaceuticals financial statements provide useful quarterly and yearly information to potential Phathom Pharmaceuticals investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Phathom Pharmaceuticals financial statements helps investors assess Phathom Pharmaceuticals' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Phathom Pharmaceuticals' valuation are summarized below:
Market Capitalization
621.6 M
Enterprise Value Revenue
18.2861
Revenue
26.3 M
Earnings Share
(5.74)
Revenue Per Share
0.44
There are currently one hundred twenty trending fundamental ratios for Phathom Pharmaceuticals that can be evaluated and compared over time across competitors. All traders should check out Phathom Pharmaceuticals' recent fundamentals against the performance from 2010 to 2024 and make sure the trends continue to evolve in the right direction. Market Cap is likely to gain to about 682 M in 2024, whereas Enterprise Value is likely to drop slightly above 214.6 M in 2024.
Check Phathom Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Phathom Pharmaceuticals' main balance sheet or income statement drivers, such as Interest Income of 8.3 M, Depreciation And Amortization of 603.8 K or Interest Expense of 44.1 M, as well as many indicators such as Price To Sales Ratio of 549, Dividend Yield of 0.0 or Days Sales Outstanding of 701. Phathom financial statements analysis is a perfect complement when working with Phathom Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Phathom Pharmaceuticals Correlation against competitors.
For more information on how to buy Phathom Stock please use our How to Invest in Phathom Pharmaceuticals guide.

Phathom Pharmaceuticals Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets242.2 M413.8 M104.7 M
Slightly volatile
Short and Long Term Debt Total73.7 M139 M32.8 M
Slightly volatile
Other Current Liabilities12.4 M7.1 M6.5 M
Slightly volatile
Total Current Liabilities26.7 M38.8 M12.6 M
Slightly volatile
Accounts Payable8.3 M12.6 M3.6 M
Slightly volatile
Cash229.6 M381.4 M99.3 M
Slightly volatile
Cash And Short Term Investments229.6 M381.4 M99.3 M
Slightly volatile
Common Stock Shares Outstanding35.6 M51.3 M19.9 M
Slightly volatile
Liabilities And Stockholders Equity242.2 M413.8 M104.7 M
Slightly volatile
Capital Surpluse458.1 M691.8 M227.8 M
Slightly volatile
Other Current Assets9.1 M13.2 M3.9 M
Slightly volatile
Other Stockholder Equity581.9 M855.9 M250.4 M
Slightly volatile
Total Liabilities510.9 M486.6 M100.3 M
Slightly volatile
Net Invested Capital98.7 M65.1 M56.3 M
Slightly volatile
Short and Long Term Debt5.1 M8.5 M4 M
Slightly volatile
Total Current Assets236.9 M397.4 M102.4 M
Slightly volatile
Short Term Debt689.7 K726 K2 M
Very volatile
Other Liabilities5.8 M8.6 M3.6 M
Slightly volatile
Property Plant And Equipment Net3.2 M3.6 M2 M
Slightly volatile
Other Assets816.6 K723.6 K483.5 K
Slightly volatile
Long Term Debt84.7 M137.8 M45 M
Slightly volatile
Common Stock Total Equity2.9 K3.5 K2.4 K
Slightly volatile
Long Term Debt Total55.8 M103.1 M40.4 M
Slightly volatile
Capital Lease Obligations1.6 M1.2 M1.1 M
Slightly volatile
Property Plant And Equipment Gross3.9 M5.7 M2.3 M
Slightly volatile
Non Current Liabilities Other325 M309.5 M52.3 M
Slightly volatile
Common Stock3.5 K5 K2.5 K
Slightly volatile
Property Plant Equipment2.4 M4 M1.9 M
Slightly volatile

Phathom Pharmaceuticals Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Interest Expense44.1 M42 M8.6 M
Slightly volatile
Selling General Administrative123.8 M117.9 M30.1 M
Slightly volatile
Other Operating Expenses129.9 M168 M56.6 M
Slightly volatile
Research Development71.7 M49.9 M30.9 M
Slightly volatile
Total Operating Expenses129.9 M167.8 M56.5 M
Slightly volatile
Cost Of Revenue158.7 K167 K123.1 K
Slightly volatile
Reconciled Depreciation450.3 K575 K171.3 K
Slightly volatile

Phathom Pharmaceuticals Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Sale Purchase Of Stock1.7 M1.7 M13.3 M
Pretty Stable
Net Borrowings61.2 M109.8 M31 M
Slightly volatile
Other Cashflows From Financing Activities91.5 M172.8 M40.4 M
Slightly volatile
Depreciation376.8 K575 K166.4 K
Slightly volatile
Other Non Cash Items25.5 M32.1 M14.5 M
Slightly volatile
Capital Expenditures1.6 M1.6 M2.1 M
Pretty Stable
Total Cash From Financing Activities386 M367.6 M90.3 M
Slightly volatile
End Period Cash Flow230.2 M384.3 M99.5 M
Slightly volatile
Change To Netincome47.3 M38.7 M25.5 M
Slightly volatile
Stock Based Compensation47.3 M45 M9.5 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio549618673
Slightly volatile
Days Sales Outstanding701788859
Slightly volatile
Stock Based Compensation To Revenue52.8259.4264.6992
Slightly volatile
Capex To Depreciation2.72.84172.1 K
Slightly volatile
EV To Sales265298325
Slightly volatile
Payables Turnover0.01260.01330.0214
Slightly volatile
Research And Ddevelopement To Revenue58.5465.8571.7029
Slightly volatile
Capex To Revenue1.922.162.3484
Slightly volatile
Cash Per Share4.667.43612.6969
Slightly volatile
Days Payables Outstanding19.7 K27.5 K26.4 K
Slightly volatile
Income Quality0.530.68250.7212
Slightly volatile
Current Ratio18.3510.24818.1152
Slightly volatile
Receivables Turnover0.340.370.4084
Slightly volatile
Graham Number19.3811.20078.7211
Slightly volatile
Capex Per Share0.03030.03190.6893
Slightly volatile
Revenue Per Share0.01060.0120.013
Slightly volatile
Interest Debt Per Share3.683.50581.1786
Slightly volatile
Debt To Assets0.320.33311.4279
Slightly volatile
Operating Cycle2.8 K3.2 K3.4 K
Slightly volatile
Days Of Payables Outstanding19.7 K27.5 K26.4 K
Slightly volatile
Ebt Per Ebit1.451.20491.1839
Slightly volatile
Long Term Debt To Capitalization1.222.11790.6419
Slightly volatile
Total Debt To Capitalization1.392.11792.3545
Slightly volatile
Quick Ratio18.3510.2178.1133
Slightly volatile
Net Income Per E B T0.81.020.8821
Slightly volatile
Cash Ratio17.619.83457.7923
Slightly volatile
Days Of Sales Outstanding701788859
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.261.01191.4808
Slightly volatile
Fixed Asset Turnover0.150.170.1846
Slightly volatile
Debt Ratio0.320.33311.4279
Slightly volatile
Price Sales Ratio549618673
Slightly volatile
Asset Turnover0.00130.00150.0016
Slightly volatile
Gross Profit Margin0.610.680.7404
Slightly volatile

Phathom Pharmaceuticals Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap682 M468.3 M406 M
Slightly volatile
Enterprise Value214.6 M225.9 M318.7 M
Slightly volatile

Phathom Fundamental Market Drivers

Cash And Short Term Investments381.4 M

Phathom Upcoming Events

27th of February 2024
Upcoming Quarterly Report
View
8th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
27th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Phathom Pharmaceuticals Financial Statements

Phathom Pharmaceuticals shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Phathom Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in Phathom Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on Phathom Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue21.1 M22.1 M
Total Revenue682 K716.1 K
Cost Of Revenue167 K158.7 K
Stock Based Compensation To Revenue 59.42  52.82 
Research And Ddevelopement To Revenue 65.85  58.54 
Capex To Revenue 2.16  1.92 
Revenue Per Share 0.01  0.01 
Ebit Per Revenue(220.79)(231.83)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Phathom Stock Analysis

When running Phathom Pharmaceuticals' price analysis, check to measure Phathom Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Phathom Pharmaceuticals is operating at the current time. Most of Phathom Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Phathom Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Phathom Pharmaceuticals' price. Additionally, you may evaluate how the addition of Phathom Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY